Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1-2
|
pubmed:dateCreated |
1989-6-5
|
pubmed:abstractText |
Nuclease-resistant phosphorothioate analogues of oligodeoxynucleotides (oligos) were synthesized by sulfurization of either internucleoside phosphite linkages, in a repetitive manner during chain extension, or internucleoside hydrogen phosphonate linkages, in a single step following chain assembly. These analogues were tested as antiviral agents against human immunodeficiency virus (HIV). In a cytopathic effect inhibition assay using HIV-uninfected susceptible T cells (tetanus toxoid-specific normal T cells) co-cultured with irradiated chronically HIV-infected cells, phosphorothioate oligomers inhibited the cytopathic effect and replication of several isolates of HIV-1 and HIV-2. Thus phosphorothioate analogues of oligos could inhibit cell-to-cell transmission of the virus as well as the infection by cell-free virus particles and also could inhibit a variety of isolates of human retroviruses.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0378-1119
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
10
|
pubmed:volume |
72
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
343-7
|
pubmed:dateRevised |
2001-11-13
|
pubmed:meshHeading |
pubmed-meshheading:3243433-Antiviral Agents,
pubmed-meshheading:3243433-Cell Line,
pubmed-meshheading:3243433-HIV,
pubmed-meshheading:3243433-Indicators and Reagents,
pubmed-meshheading:3243433-Oligodeoxyribonucleotides,
pubmed-meshheading:3243433-Structure-Activity Relationship,
pubmed-meshheading:3243433-Thionucleotides,
pubmed-meshheading:3243433-Virus Replication
|
pubmed:year |
1988
|
pubmed:articleTitle |
Synthesis of phosphorothioate analogues of oligodeoxyribonucleotides and their antiviral activity against human immunodeficiency virus (HIV).
|
pubmed:affiliation |
Clinical Oncology Program, National Cancer Institute, Bethesda, MD 20892.
|
pubmed:publicationType |
Journal Article
|